External evaluation of published population pharmacokinetic models of polymyxin B

Eur J Clin Pharmacol. 2021 Dec;77(12):1909-1917. doi: 10.1007/s00228-021-03193-y. Epub 2021 Aug 3.

Abstract

Objectives: Several population pharmacokinetics (popPK) models for polymyxin B have been constructed to optimize therapeutic regimens. However, their predictive performance remains unclear when extrapolated to different clinical centers. Therefore, this study aimed to evaluate the predictive ability of polymyxin B popPK models.

Methods: A literature search was conducted, and the predictive performance was determined for each selected model using an independent dataset of 20 patients (92 concentrations) from the Third Xiangya Hospital. Prediction- and simulation-based diagnostics were used to evaluate model predictability. The influence of prior information was assessed using Bayesian forecasting.

Results: Eight published studies were evaluated. In prediction-based diagnostics, the prediction error within ± 30% was over 50% in two models. In simulation-based diagnostics, the prediction- and variability-corrected visual predictive check (pvcVPC) showed satisfactory predictivity in three models, while the normalized prediction distribution error (NPDE) tests indicated model misspecification in all models. Bayesian forecasting demonstrated a substantially improvement in the model predictability even with one prior observation.

Conclusion: Not all published models were satisfactory in prediction- and simulation-based diagnostics; however, Bayesian forecasting improved the predictability considerably with priors, which can be applied to guide polymyxin B dosing recommendations and adjustments for clinicians.

Keywords: External evaluation; Polymyxin B; Population pharmacokinetics.

MeSH terms

  • Bayes Theorem
  • Humans
  • Immunosuppressive Agents / pharmacokinetics*
  • Models, Biological*
  • Polymyxin B / pharmacokinetics*

Substances

  • Immunosuppressive Agents
  • Polymyxin B